Vivani Medical, Inc. Common Stock (DE) VANI

Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.

• The Motley Fool 29 ago

  Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

  Novo Nordisk, which pioneered GLP-1 weight-loss drugs but lost market leadership to Eli Lilly, is attempting a comeback through product innovation. The company has launched a pill version of Wegovy and partnered with Vivani Medical to develop an implant that could deliver the drug once or twice yearly, potentially revolutionizing convenience in the GLP-1 market. While Eli Lilly maintains a stronger market position and higher valuation, Novo Nordisk's continued innovation could help it regain competitive ground.

  

• GlobeNewswire Inc. 14 jul

  Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream

  EmergingGrowth.com announces the 94th Emerging Growth Conference scheduled for July 15-16, 2026, featuring presentations from 20+ small-cap and emerging growth companies across sectors including mining, technology, healthcare, and renewable energy. The virtual conference allows companies to present their strategies, products, and announcements to the investment community.

  

• GlobeNewswire Inc. 2 jul

  Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

  Vivani Medical announced a definitive merger agreement to merge its wholly owned subsidiary Cortigent, Inc. with ClearOne, Inc. Under the transaction, Cortigent will become a wholly owned subsidiary of ClearOne, which will be renamed Cortigent Holdings, Inc. and trade under ticker symbol 'CRGT'. ClearOne will raise $10-15 million in concurrent financing. Vivani will receive 12.5 million shares and own 59.4-67.5% of the combined company. The transaction is expected to close in Q3 2026.